Genomic Analysis to Identify a Predictive Biomarker for Immunotherapy
Recruiting · NCT03578185 · Observational (researchers observe without assigning treatment) · Lead sponsor: Samsung Medical Center
View the official record on ClinicalTrials.gov →What this trial is about
This study is designed to identify the predictive biomarker for immunotherapy using patient samples (tumor tissue, blood, fecal material) who treated with immune checkpoint inhibitor.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- aged above or equal to 18
- Histologically confirmed lung cancer patients
- Patient treated with immune checkpoint inhibitor
- Exculsion Criteria:
Where it is running
3 locations listed.
- Samsung Medical Center - Seoul, Gangnam-gu, South Korea
- Seoul National University Hospital - Seoul, Joungro-gu, South Korea
- Asan Medical Center - Seoul, Songpa-gu, South Korea